SkyePharma gives update on talks with FDA

SkyePharma Plc said it is reviewing all of its options following a meeting with the US Food and Drug Administration during which the agency outlined the work that would be required to meet its approval criteria for Flutiform, an asthma drug.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom